We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




ATP-Triggered Nanoparticles Effectively Kill Breast Cancer Cells in Mouse Model

By LabMedica International staff writers
Posted on 25 Mar 2014
Print article
Image: The structure of the ATP-triggered nanoparticle (left) and how the nanoparticles shrink a tumor (right) (Photo courtesy of North Carolina State University).
Image: The structure of the ATP-triggered nanoparticle (left) and how the nanoparticles shrink a tumor (right) (Photo courtesy of North Carolina State University).
A recent paper describes novel nanoparticles that transport toxic anticancer drugs specifically to tumor cells where they are engulfed and induced to release their cargo by the high intracellular concentration of adenosine-5'-triphosphate (ATP).

The nanoparticles, which were composed of a liposomal core enclosed in a cross-linked hyaluronic acid (HA)-based gel shell (designated Gelipo), were devised by a team of investigators at North Carolina State University (Raleigh, USA) and the University of North Carolina (Chapel Hill, USA). The cores of the nanoparticles were loaded with an ATP-binding aptamer-incorporated DNA motif that was able to selectively release incorporated molecules of the cancer drug doxorubicin (Dox) via a conformational switch when in an ATP-rich environment. Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids.

The nanoparticles were tested on a mouse cancer model. Following injection of the nanoparticles into mice carrying the MDA-MB-231 xenograft tumor, the HA shells were degraded by hyaluronidase (HAase) enzyme that was concentrated in the tumor environment. This resulted in the rapid internalization of the liposomes, which, in turn, caused release of the aptamer-DNA-Dox molecules into the tumor cells. The high concentration of ATP inside the tumor cells then caused the aptamer-DNA molecules to unfold and release the Dox, which killed the cells.

Results reported in the March 11, 2014, online edition of the journal Nature Communications showed that the new type of nanoparticles were 3.6 times more effective against MDA-MB-231 human breast cancer cells than previously tested nanoparticles that did not incorporate an ATP-triggered component.

"This is a proof of concept, but we have demonstrated there is now a new tool for introducing anti-cancer drugs directly into cancer cells—and that should make drug treatments significantly more effective," said senior author Dr. Zhen Gu, assistant professor in the joint biomedical engineering program at North Carolina State University and the University of North Carolina. "We also believe that we will be able to make the technique even more targeted by manipulating ATP levels in specific areas."

Related Links:

North Carolina State University
University of North Carolina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)

New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.